Literature DB >> 9638906

Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome: a review of diagnosis and management.

C J Saphier1, J T Repke.   

Abstract

Hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome is a form of severe preeclampsia that threatens the gravida and her fetus. In this report, the diagnostic criteria and maternal and fetal risks of HELLP are defined. Prompt recognition and treatment in tertiary centers is emphasized, because the prognosis can be adversely affected by delayed or less than optimal diagnosis and treatment. Management guidelines are offered for treating this disorder. The potential roles of corticosteroids, plasmapheresis, and expectant management are critically evaluated. Subsequent pregnancy outcome, contraception, and preventative strategies are considered.

Entities:  

Keywords:  Biology; Diseases; Examinations And Diagnoses; Hematological Effects; Hemic System; Hepatic Effects; Literature Review; Physiology; Preeclampsia--prevention and control; Pregnancy Complications; Signs And Symptoms; Treatment

Mesh:

Year:  1998        PMID: 9638906     DOI: 10.1016/s0146-0005(98)80044-x

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  3 in total

1.  Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction.

Authors:  Anouk Pels; Janus C Jakobsen; Wessel Ganzevoort; Christiana A Naaktgeboren; Wes Onland; Aleid G van Wassenaer-Leemhuis; Christian Gluud
Journal:  Trials       Date:  2019-01-11       Impact factor: 2.279

2.  COVID-19: A Cause of HELLP Syndrome? A Case Report.

Authors:  Ebubekir Arslan
Journal:  Int J Womens Health       Date:  2022-04-26

3.  Reduced syncytin-1 expression levels in placental syndromes correlates with epigenetic hypermethylation of the ERVW-1 promoter region.

Authors:  Matthias Ruebner; Pamela L Strissel; Arif B Ekici; Elisabeth Stiegler; Ulf Dammer; Tamme W Goecke; Florian Faschingbauer; Fabian B Fahlbusch; Matthias W Beckmann; Reiner Strick
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.